Heart failure & cardiomyopathies
Cost–Utility of Cardiac Contractility Modulation in Patients with Heart Failure with Reduced Ejection Fraction in Italy
Main finding · Incremental cost-utility ratio (base case)Result — go to the resultIncremental cost-utility ratio €7034 QALYAuthors' conclusion
For patients with heart failure with reduced ejection fraction, CCM therapy could be cost-effective when taking a lifetime horizon.
Study context
- Population
- Patients with HFrEF in ItalyFIX trials as main data sources
- Comparison
- Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT) vs OMT alone
- Outcome
- Incremental cost-utility ratio (€/QALY)
- Follow-up
- Lifespan time horizon
Methodological detailsMarkov model, lifespan time horizon, deterministic and probabilistic sensitivity analyses, value of information analysis
- Markov model
- Lifespan time horizon
- Deterministic and probabilistic sensitivity analyses
- Value of information analysis
Main finding
Incremental cost-utility ratio (base case)
Incremental cost-utility ratio
€7034 QALY
As reported in the abstract
Further findings
Probability of being cost-effective (cost-effectiveness acceptability curve (CEAC) and cost-effectiveness acceptability frontier (CEAF))
- CCM plus OMT had the highest probability of being cost-effective for all willingness to pay levels above €5600/QALY, tested up to €50 000/QALY
Expected value of perfect information (EVPI) per patient
- EVPI per patient at willingness to pay threshold of €30 000/QALY
- €124 412
Original publication
Cost–Utility of Cardiac Contractility Modulation in Patients with Heart Failure with Reduced Ejection Fraction in Italy. ESC Heart Fail. Published 9 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →